SEC Comment Letter 0000000000-26-003177 to Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc.
Date: March 30, 2026 · CIK: 0001576885 · Accession: 0000000000-26-003177
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294649
Letter
Re: Acumen Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 26, 2026 File No. 333-294649 Dear Daniel O'Connell:
March 30, 2026
Daniel O'Connell Chief Executive Officer Acumen Pharmaceuticals, Inc. 1210-1220 Washington Street, Suite 210 Newton, Massachusetts 02465
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Thomas J. Danielski, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 30, 2026 Daniel O'Connell Chief Executive Officer Acumen Pharmaceuticals, Inc. 1210-1220 Washington Street, Suite 210 Newton, Massachusetts 02465 Re: Acumen Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 26, 2026 File No. 333-294649 Dear Daniel O'Connell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas J. Danielski, Esq. </TEXT> </DOCUMENT>